Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial

Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial

Abstract Antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) are widely used for HER2-positive metastatic breast cancer, but their efficacy in the neoadjuvant setting remains under investigation. The MUKDEN 06 trial (NCT05426486), a multicentre, randomised, phase 2b study, compared...

Full description

Saved in:
Bibliographic Details
Main Authors: Nan Niu, Jinqi Xue, Guanglei Chen, Fang Qiu, Qianshi Xu, Xinyu Zheng, Chao Liu, Yafei Zhao, Xi Gu, Yi Zhao, Hong Xu, Hao Zhang, Guijin He, Ke Li, Pengfei Li, Xiaoying Chen, Yong Li, Shuo Wang, Demiao Zhu, Tong Liu, Fei Xing, Yongqing Xu, Ye Han, Meiyue Tang, Mingxin Liu, Gege Jiao, Xiaofan Jiang, Tony Yuen, Zheng Pang, Caigang Liu
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-61213-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items